Loading
A lung cancer oncologist who has helped test checkpoint inhibitors and next-generation ADCs in Korean patients.
Se-Hoon Lee is Professor of Internal Medicine at Seoul National University Hospital, working in thoracic oncology and immunotherapy. He has helped test checkpoint inhibitors and next-generation antibody-drug conjugates in Korean patients, including the datopotamab deruxtecan and tarlatamab programmes in non-small-cell and small-cell lung cancer. His publications include a phase 2 trial of vandetanib in pretreated lung cancer harbouring RET rearrangements and a study of the clonal history and genetic predictors of transformation from lung adenocarcinoma into small-cell carcinoma. His interests are lung cancer, immunotherapy and small-cell lung cancer.
| Title | Journal | Year |
|---|---|---|
| Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial | Annals of Oncology | 2017 |
| Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas | Journal of Clinical Oncology | 2017 |
| MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer | New England Journal of Medicine | 2024 |
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Datopotamab deruxtecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Tarlatamab, Small-cell lung cancer.
Shares Tarlatamab, Small-cell lung cancer.
Shares MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer, Datopotamab deruxtecan, Non-small-cell lung cancer.
Shares Tarlatamab, Small-cell lung cancer.